ROCHELLE PARK, NJ â ZRG Partners has announced the findings for the first quarter Global Life Sciences Hiring Index. Hiring activity continued to grow, posting over 20% higher than a year ago. Medical Device hiring increased 20% over last quarter and hiring activity reached historical highs. Despite quarterly decreases in Outsourcing Services and Pharma & Biotech, hiring activity overall was +5% over the prior quarter. ZRG European President and Global Practice Head of Life Sciences, Adam El Din commented, “The demand for medical equipment from emerging countries will outpace demand from developed countries in the next 5 years. While the U.S. and Europe markets are growing at single digits, Indian and Chinese markets are growing at 20â25% a year. The demand for selfâmedication and homeâbased treatment is increasing, with more and more patients resorting to both the diagnosis and treatment of specific diseases at home.” David Fortier, Managing Director â Global Life Sciences added, “Leaders in the various sectors continue to invest heavily on talent and sustain historically robust levels of hiring. While companies seek to build efficient organizations, new technologies and increasingly complex market dynamics create demand for new skill sets and capabilities in the workforce.” About ZRG Partners  ZRG Partners, LLC is a global authority on talent management in the Life Sciences, Pharmaceutical and Medical Device markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions. The Global Life Sciences Hiring Index analysis utilizes a proprietary algorithm that looks at hiring within selected benchmark companies in three distinct segments. The companies in the index generate over $630 billion in revenues and employ over 1.5 million people globally. ZRG Partners conducts extensive direct market research in developing the data that drives the Index.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.